MAINTAIN (Mucosal AblatIoN Therapy After INcretins)
NCT06734312
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to assess the effect of gastric fundal mucosal ablation (GFMA) on weight trajectory following discontinuation of once-weekly semaglutide or tirzepatide in adults with obesity. In this study, GFMA will be performed on patients who have experienced > 10% weight loss with GLP-1 therapy and who plan to discontinue use of GLP-1 medications for the duration of the study.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Obesity and Obesity-related Medical Conditions
- Obesity and Overweight
- Obesity Prevention
- Obesity Recidivism
- GLP-1
- Ablation Techniques
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 21 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Dr. Christopher McGowan
- Last updated on ClinicalTrials.gov
- March 21, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
North Carolina · 1
- True You Weight Loss · Cary, NC
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.